Regen-cov Coupons & Cost Discounts

The combination of casirivimab and imdevimab is a product that has been used to treat COVID-19 on an emergency/interim use basis. It is used by people 12 years of age and older who have recently tested positive for coronavirus, have had mild to moderate symptoms for no more than 10 days, and are not hospitalized. This product has also been used in the US to help prevent COVID-19 infection in people who have a high risk for infection after exposure to someone infected with COVID-19. Some conditions that increase risk of infection after exposure include: not being fully vaccinated, having had close contact, or being at high risk of close contact due to your housing conditions (such as a nursing home or prison). To receive this product you must also be at high risk for COVID-19 complications due to older age, obesity, or ongoing medical conditions (such as lung or heart disease or diabetes, among others). Talk to your doctor about the risks and benefits of treatment with casirivimab and imdevimab. Casirivimab and imdevimab are antibodies which, when given soon after infection, can neutralize the coronavirus and may prevent worsening of COVID-19 symptoms. More information about casirivimab and imdevimab is available from the patient information sheet provided by your health care professional. If you are enrolled in a study, information should be provided by the doctor via the Informed Consent Form. There is limited information about how safe and effective the combination of casirivimab and imdevimab is for treating COVID-19. Study results show that casirivimab and imdevimab may help people who have recently tested positive for coronavirus stay out of the hospital. This product is not for use by people who are hospitalized due to COVID-19, or who need supplemental oxygen or a ventilator due to COVID-19. The information in this document reflects emerging data, which is evolving and subject to reassessment. Users should be aware of these considerations in their review of casirivimab and imdevimab, and it is always the responsibility of treating practitioners to exercise independent judgment in making care decisions.